Tecentriq 840 mg/14 mL solution for intravenous infusion Images
Generic Name: atezolizumab
This medication has been identified as Tecentriq 840 mg/14 mL solution for intravenous infusion. It is supplied by Genentech, Inc.
Tecentriq is used in the treatment of Hepatocellular Carcinoma; Small Cell Lung Cancer; Alveolar Soft Part Sarcoma; Melanoma; Non Small Cell Lung Cancer and belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors). Tecentriq 840 mg/14 mL solution for intravenous infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Tecentriq
- Generic Name
- atezolizumab
- Strength
- 840 mg/14 mL solution for intravenous infusion
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0918
More about Tecentriq (atezolizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
